Olmesartan Medoxomil in Pediatric Hypertension

Phase 3, randomised, double-blind trial of olmesartan in hypertension (HTN) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 at 3 weeks and Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 at 3 weeks. Started May 2005; status: completed.